ArticleInternational journal of nanomedicine2025
Quercetin-Loaded Nanoparticle-Modified Decellularized Tissue-Engineered Vascular Graft Regulates Macrophage Polarization and Promotes In Vivo Graft Remodeling.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Quercetin-Based Advanced Delivery Systems - From Multimodal Nano-theranostics to Microneedles: a Recent Update on Their Preclinical Studies.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Arteriovenous graft (AVG) is an important option for establishing hemodialysis access in patients with end-stage chronic kidney disease (CKD). Decellularized tissue-engineered vascular graft (dTEVG), due to its excellent biocompatibility and regenerative potential, holds promise for use in AVG; however, poor remodeling remains a challenge. Quercetin (Qu) can effectively regulate macrophage polarization and promote tissue remodeling and regeneration, yet its low bioavailability limits its clinical application. Methods: Here, we developed a nano-localized drug delivery system using Qu-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles (Qu@PNPs), prepared via a nanoprecipitation method and subsequently modified onto the surface of dTEVG. In vitro and in vivo experiments were performed to assess the biocompatibility of Qu@PNPs and their effect on macrophage polarization. Additionally, the impact of Qu@PNPs modification on dTEVG remodeling was evaluated in both subcutaneous and AVG rat models. Results: Our study results demonstrated that Qu@PNPs exhibited good biocompatibility and achieved sustained drug release on dTEVG. Furthermore, these drug-loaded nanoparticles inhibited M1 macrophage polarization while promoting M2 polarization, significantly improving the in vivo remodeling of dTEVG, as evidenced by increased early recellularization and peripheral neovascularization. Conclusion: Together, the development of the nano-localized drug delivery system effectively enhanced the application of Qu, providing experimental evidence for its use in dTEVG. Additionally, it offers new strategies and approaches for optimizing dTEVG design and clinical translation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.